Compare Cytokinetics Inc (CYTK) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MBS ETF — how do they compare? Cytokinetics Inc trades at $62.52 (market cap $8.62B), while iShares MBS ETF trades at $89.44 (market cap $35.41B). The key difference: iShares MBS ETF is far larger — about 4.1× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares MBS ETF for 96 Days on average.
| CYTK | MBB | |
|---|---|---|
Market Cap | $8.62B | $35.41B |
Volume | 2,594,626 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $87.26 | $96.91 |
52-Week Low | $54.76 | $89.09 |
Typical Hold Time | 19 Days | 96 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
MBB, the iShares MBS ETF, trades at $89.54, up 0.36% on the day but showing a bearish technical signal overall. The ETF has faced significant short interest growth of 98.3% in September 2026, reaching 6.57 million shares, and recently hit a 52-week low. Recent news highlights concerns over intermediate duration risk amid potential rate hikes, though institutional buying from firms like Corient Private Wealth and Baird Financial Group provides some support. Key technical indicators show oversold conditions on the 12-day RSI but strong selling pressure from moving averages.
The outlook for MBB remains cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. While dividend payments offer income, rising rates and inflation pressures pose downside risks. Analyst sentiment is neutral to bearish, with the ETF's performance heavily tied to Federal Reserve policy. Investors should weigh the high yield against duration risk in a tightening cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
